The European Patent Office announces its Intention to grant Stayble’s patent for the treatment of disc herniation

Report this content

Stayble Therapeutics AB (“Stayble” or “the Company”) announced today that the European Patent Office (EPO) has issued an "Intention to Grant" for the Company’s patent for the treatment of disc herniation with STA363. "Intention to Grant" means that only a formal process remains before Stayble can receive approved patents in countries affiliated with the EPO.

The patent, titled "A composition for use in the treatment of intervertebral disc herniation," was filed at the end of 2020 and provides IP protection until 2040. Additionally, there is the possibility of applying for a five-year patent term extension in selected countries, including the USA and Japan. The patent covers using STA363 to treat pain arising from herniated discs.

This notification marks a significant milestone for the Company and follows a previously positive international search report from European authorities. With these advancements, we see a promising opportunity to obtain additional approved national patents. The patent has previously been approved in South Africa.

Andreas Gerward, CEO of Stayble, comments:
“The EPO’s intention to grant our patent provides broad protection for our innovation and covers key markets for our product STA363. The patent covers using STA363 for treating disc herniation-related pain, offering us the protection we need to advance our business. Strong patent protection is crucial in our industry and future partnership discussions. Approval from the EPO is a significant step toward global protection."

Stayble can now apply for approval in the following countries: Albania, Austria, Belgium, Bulgaria, Switzerland, Cyprus, Czech Republic, Germany, Denmark, Estonia, Spain, Finland, France, United Kingdom, Greece, Croatia, Hungary, Ireland, Iceland, Italy, Liechtenstein, Lithuania, Luxembourg, Latvia, Monaco, North Macedonia, Malta, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Sweden, Slovenia, Slovakia, San Marino, and Turkey.

For more information

Andreas Gerward, CEO of Stayble Therapeutics AB

Mail: andreas.gerward@stayble.se

Phone: +46 730 808 397

 

About Stayble Therapeutics AB

Stayble is a clinical pharmaceutical company developing the injection treatment STA363 for chronic disc herniation (LDH). Stayble's vision is to offer patients a simple and effective treatment that targets the underlying cause of the patient's chronic pain and provides lasting pain relief and increased physical function. The treatment is aimed at patients who are not helped by physical therapy and painkillers and is a single injection that is expected to last a lifetime and requires minimal rehabilitation. After convincing data from previous pre-clinical and clinical studies (phase 1b and 2b) in degenerative disc disease, which show a volume reduction of the discs, the Company is currently conducting a phase 1b study for the treatment of herniated discs.

The company's Certified Adviser is Svensk Kapitalmarknadsgranskning AB.